Search Results - "Lauring B"

Author Correction: Environmentally driven immune imprinting protects against allergy.

Authors: Erickson, S. Lauring, B. Cullen, J. et al.

Source: Nature. Feb2026, p1-1.

Environmentally driven immune imprinting protects against allergy.

Authors: Erickson, S. Lauring, B. Cullen, J. et al.

Source: Nature. Jan2026, p1-10.

This result is not displayed to guests.
Login for full access.

Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.

Authors: Lauring B Dishy V Luo W et al.

Source: Journal of Clinical Pharmacology. Dec2009, Vol. 49 Issue 12, p1426-1435. 10p.

CHOLESTEROL AND STEROID SYNTHESIZING SMOOTH ENDOPLASMIC RETICULUM OF ADRENOCORTICAL CELLS CONTAINS HIGH LEVELS OF TRANSLOCATION APPARATUS PROTEINS.

Authors: Black, V. H. Sanjay, A. van Leyen, K. et al.

Source: Endocrine Research. Nov2002, Vol. 28 Issue 4, p425-430. 6p.

Gut enteroendocrine cell activation using a combination of GPR119 and GPR40 agonists results in synergistic hormone secretion in mice and humans.

Authors: Sebhat IK Murphy MJM Zheng S et al.

Source: Cell metabolism [Cell Metab] 2026 Jan 06; Vol. 38 (1), pp. 50-64.e12. Date of Electronic Publication: 2025 Dec 02.

Publication Type: Journal Article

Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101233170 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-7420 (Electronic) Linking ISSN: 15504131 NLM ISO Abbreviation: Cell Metab Subsets: MEDLINE

Combined agonism of nutrient receptors GPR40 and GPR119 with K-757 and K-833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus.

Authors: Crutchlow M Liu J Romero C et al.

Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2025 Dec; Vol. 27 (12), pp. 7198-7209. Date of Electronic Publication: 2025 Sep 15.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Clinical Trial, Phase II

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

Combined GPR40 and GPR119 full agonism with K-757 and K-833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM.

Authors: Crutchlow M Liu J Hernandez-Illas M et al.

Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2025 Nov; Vol. 27 (11), pp. 6264-6274. Date of Electronic Publication: 2025 Aug 06.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

Discovery of Gut-Targeted GPR40 Agonist K-757 and GPR119 Agonist K-833, a Combination Treatment for Metabolic Disorders.

Authors: Moyes CR He S Mathieu S et al.

Source: Journal of medicinal chemistry [J Med Chem] 2025 Aug 14; Vol. 68 (15), pp. 15339-15357. Date of Electronic Publication: 2025 Jul 24.

Publication Type: Journal Article

Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.

Authors: Ji L Liu Y Miao H et al.

Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Jun; Vol. 21 (6), pp. 1474-1482. Date of Electronic Publication: 2019 Apr 05.

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.

Authors: Gallo S Charbonnel B Goldman A et al.

Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Apr; Vol. 21 (4), pp. 1027-1036. Date of Electronic Publication: 2019 Feb 14.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.

Authors: Aronson R Frias J Goldman A et al.

Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Jun; Vol. 20 (6), pp. 1453-1460. Date of Electronic Publication: 2018 Feb 23.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.

Authors: Pratley RE Eldor R Raji A et al.

Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 May; Vol. 20 (5), pp. 1111-1120. Date of Electronic Publication: 2018 Jan 25.

Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.

Authors: Dagogo-Jack S Liu J Eldor R et al.

Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Mar; Vol. 20 (3), pp. 530-540. Date of Electronic Publication: 2017 Oct 23.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).

Authors: Rosenstock J Frias J Páll D et al.

Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Mar; Vol. 20 (3), pp. 520-529. Date of Electronic Publication: 2017 Oct 02.

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.

Authors: Lauring B Li XS Liu Y et al.

Source: Journal of clinical pharmacology [J Clin Pharmacol] 2014 Nov; Vol. 54 (11), pp. 1247-55. Date of Electronic Publication: 2014 Jun 06.

Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.

Authors: Lauring B Liu Y Li XS et al.

Source: Journal of clinical pharmacology [J Clin Pharmacol] 2014 Jul; Vol. 54 (7), pp. 765-75. Date of Electronic Publication: 2014 Mar 06.

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.

Authors: Engel SS Golm GT Lauring B

Source: Diabetes [Diabetes] 2013 Oct; Vol. 62 (10), pp. e18.

Publication Type: Letter; Comment

Journal Info: Publisher: American Diabetes Association Country of Publication: United States NLM ID: 0372763 Publication Model: Print Cited Medium: Internet ISSN: 1939-327X (Electronic) Linking ISSN: 00121797 NLM ISO Abbreviation: Diabetes Subsets: MEDLINE

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.

Authors: Lauring B Taggart AK Tata JR et al.

Source: Science translational medicine [Sci Transl Med] 2012 Aug 22; Vol. 4 (148), pp. 148ra115.

Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.

Authors: Hollander P Hill J Johnson J et al.

Source: Current medical research and opinion [Curr Med Res Opin] 2019 Aug; Vol. 35 (8), pp. 1335-1343. Date of Electronic Publication: 2019 Mar 25.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE